|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
48 Weeks TDF Treatment Results in Potent Viral
Suppression and A Favorable Safety Profile in Chinese
Chronic Hepatitis B Patients
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), June 2013,
Singapore
JL Hou1*, ZL Gao2, Q Xie3, JM Zhang4, JF Sheng5, J Cheng6, CW Chen7,
Q Mao8, W Zhao9, H Ren10 , DM Tan11, JQ Niu12, SJ Chen13, C Pan14, H
Tang15, H Wang16, YM Mao17,JD Jia18, Q Ning19, M Xu20, SM Wu20, J Li22,
XX Zhang3; Y Ji23; J Dong24, J Li24
* Corresponding Author: Jin Lin Hou M.D. Director & Professor, Hepatology Unit
and Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
1Nanfang Hospital, Guangzhou, China; 23rd Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China; 3Ruijin Hospital Affiliated to Jiaotong University,
Shanghai, China; 4Huashan Hospital Affiliated to Fudan University, Shanghai,
China;51st Affiliated Hospital of ZheJiang University, Hangzhou, China; 6Beijing
Ditan Hospital, Beijing, China; 7Shanghai the 85th Hospital Affiliated to Nanjing
Military, Shanghai, China; 8Southwest Hospital, Third Military Medical University,
Chongqing, China; 92nd Hospital of Nanjing, Nanjing, China; 102nd Affiliated
Hospital Chongqing Medical University, Chongqing, China;11Xiangya Hospital
Central-South University, Changsha, China; 121st Affi liated Hospital of Jilin
University, Changchun, China; 13Jinan Hospital for Infectious Disease, Jinan,
China; 14 Fuzhou Infectious Disease Hospital, Fuzhou, China; 15West China
Hospital, Sichuan University, Chengdu, China; 16Peking University People’s
Hospital, Beijing, China; 17Renji Hospital Affiliated to Shanghai JiaoTong
University, Shanghai, China; 18Beijing Friendship Hospital Affi liated to Capital
University, Beijing, China; 19Tongji Hospital of Tongji Medical College, Wuhan,
China; 20Guangzhou Eighth Municipal People’s Hospital, Guangzhou, China;
21Shanghai Public Health Clinical Center, Shanghai, China; 22The First Affiliated
Hospital with Nanjing Medical University, Nanjing, China; 23Zhongshan Hospital,
Fudan University, Shanghai, China ; 24GlaxoSmithKline R&D China.
CONCLUSIONS
At Week 48, TDF demonstrated high potency and a favorable safety profile in Chinese CHB patients. No TDF resistance was observed.
结论
48周时，TDF展示中国CHB患者高效力和良好的安全性。没有TDF耐药。
|
|
发表于 2013-6-20 20:09
